دورية أكاديمية
Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease
| العنوان: | Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease |
|---|---|
| المؤلفون: | Bay, Pierre, de Chambrun, Marc, Rothstein, Vincent, Mahevas, Matthiéu, de Prost, Nicolas, Roux, Antoine, Zuber, Benjamin, Biet, Dominique Israël, Hervier, Baptiste, Tazi, Abdellatif, Mouthon, Luc, Mekinian, Arsène, Deligny, Christophe N., Borie, Raphaël, Meurice, Jean Claude, Meyer, Alain, Priou, Pascaline, Savale, Laurent, de Saint Martin, Luc, Gallay, Laure, Cottin, Vincent, Blanchard, Elodie, Brillet, Pierre Yves, Khafagy, Philippe, Benveniste, Olivier, Nunes, Hilario, Uzunhan, Yurdagül, Allenbach, Yves |
| المساهمون: | Service de pneumologie Avicenne, Hôpital Avicenne AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition CHU Pitié Salpêtrière (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service de pneumologie Hôpital Foch, Hôpital Foch Suresnes, Université Paris Cité (UPCité), Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Cochin AP-HP, CHU Saint-Antoine AP-HP, CHU de la Martinique Fort de France, AP-HP - Hôpital Bichat - Claude Bernard Paris, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Hôpital Morvan Brest, Hospices Civils de Lyon (HCL), Hôpital Edouard Herriot CHU - HCL, Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Service de radiologie Avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P - U1272 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-UFR Santé Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord-Université Sorbonne Paris Nord, PB, MPdC, VR, MM, NdP, AR, BZ, DIB, BH, AM, CD, JCM, AM, PP, LdSM, LG, PK, OB, YA declare that they have no competing interests. AT reports personal fees from Bristol Myers Squibb and Chiesi, and travel accomodation fees from AstraZeneca, Boehringer Ingelheim, Teva, and Vitalaire, outside the submitted work. LM reports personal fees from Actelion/Johnson & JohnsonJohnson & Johnson, grants from LFB, non-financial support from Octapharma, and non-financial support from Grifols, outside the submitted work. RB reports grants and personal fees from Roche, personal fees from Boerhinger Ingelheim and Savapharma, outside the submitted work. LS reports personal fees from Actelion and Bayer, grants and personal fees from GSK, outside the submitted work. VC reports non-financial support from Actelion, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Bayer/MSD, other from Gilead, personal fees from Novartis, personal fees, non-financial support and other from Roche SAS, personal fees and non-financial support from Sanofi, personal fees from Promedior, other from Celgene, personal fees from Galapagos, other from Galecto, personal fees from Astra Zeneca, personal fees from ReImagine, personal fees from Soun, personal fees from BMS, personal fees from PPDi, personal fees from IQVIA, personal fees from Exepi, personal fees from Shionogi, none of which was related to this work. EB reports having received consultancy or speaker fees, travel support from Pfizer, MSD, Novartis, Gilead, Roche, Boehringer Ingelheim, SOS Oxygene, ISIS Medical, outside the submitted work. PYB reports grants from Laboratoire Boehringer Ingelheim and Laboratoire Roche, and personal fees from Laboratoire Boehringer Ingelheim and Laboratoire Roche, outside the submitted work. HN reports grants from Boehringer Ingelheim and Roche/Genentech, personal fees from Actelion Pharmaceuticals, Boehringer Ingelheim, Galapagos, and Roche/Genentech, outside the submitted work. YU reports personal fees from Boehringer Ingelheim and Roche, and grants and non-financial support from Oxyvie, outside the submitted work. |
| المصدر: | ISSN: 0896-8411. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| مصطلحات موضوعية: | Dermatomyositis, Intensive care unit, MDA5, Plasma exchange, Rapidly progressive interstitial lung disease, [SDV.IMM]Life Sciences [q-bio]/Immunology |
| الوصف: | International audience ; Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD. Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival. Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38–264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan–Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease. Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36323067; hal-03950145; https://hal.science/hal-03950145Test; PUBMED: 36323067 |
| DOI: | 10.1016/j.jaut.2022.102941 |
| الإتاحة: | https://doi.org/10.1016/j.jaut.2022.102941Test https://hal.science/hal-03950145Test |
| حقوق: | http://hal.archives-ouvertes.fr/licences/copyrightTest/ |
| رقم الانضمام: | edsbas.AE0745E1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jaut.2022.102941 |
|---|